Do analysts recommend UNCY or PYRGF?

Unicycive Therapeutics currently has a consensus price target of $18.25, suggesting a potential upside of 332.46%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor UNCY or PYRGF?

In the previous week, Unicycive Therapeutics had 34 more articles in the media than PyroGenesis Canada. MarketBeat recorded 37 mentions for Unicycive Therapeutics and 3 mentions for PyroGenesis Canada. Unicycive Therapeutics' average media sentiment score of 0.24 beat PyroGenesis Canada's score of 0.22 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral PyroGenesis Canada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PYRGF or NMRA?

Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 1,214.55%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neumora Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts rate PYRGF or NRXP?

NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 1,089.66%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NRx Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is PYRGF or NRXP more profitable?

PyroGenesis Canada has a net margin of -115.14% compared to NRx Pharmaceuticals' net margin of -691.81%. Company Net Margins Return on Equity Return on Assets PyroGenesis Canada -115.14% N/A -60.81% NRx Pharmaceuticals -691.81% N/A -63.92%

Does the media refer more to PYRGF or NRXP?

In the previous week, NRx Pharmaceuticals had 5 more articles in the media than PyroGenesis Canada. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 3 mentions for PyroGenesis Canada. NRx Pharmaceuticals' average media sentiment score of 0.29 beat PyroGenesis Canada's score of 0.22 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PYRGF or MNOV?

MediciNova has a consensus price target of $7.75, indicating a potential upside of 335.39%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media refer more to PYRGF or MNOV?

In the previous week, MediciNova had 6 more articles in the media than PyroGenesis Canada. MarketBeat recorded 9 mentions for MediciNova and 3 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.22 beat MediciNova's score of 0.19 indicating that PyroGenesis Canada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PYRGF or IMUX?

Immunic has a consensus target price of $35.43, indicating a potential upside of 345.08%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Immunic 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.00

PyroGenesis Canada (PYRGF) Competitors

$0.18 0.00 (-1.59%)

As of 10:13 AM Eastern

Compare

PYRGF vs. UNCY, NMRA, NRXP, MNOV, and IMUX

Should you buy PyroGenesis Canada stock or one of its competitors? PyroGenesis Canada's main competitors and comparable companies include Unicycive Therapeutics (UNCY), Neumora Therapeutics (NMRA), NRx Pharmaceuticals (NRXP), MediciNova (MNOV), and Immunic (IMUX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PyroGenesis Canada compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Unicycive Therapeutics currently has a consensus price target of $18.25, suggesting a potential upside of 332.46%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Unicycive Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Unicycive Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	172.83	-$26.56M	-$1.75	N/A
PyroGenesis Canada	$9.14M	4.53	-$21.12M	-$0.04	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
PyroGenesis Canada	-115.14%	N/A	-60.81%

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 34 more articles in the media than PyroGenesis Canada. MarketBeat recorded 37 mentions for Unicycive Therapeutics and 3 mentions for PyroGenesis Canada. Unicycive Therapeutics' average media sentiment score of 0.24 beat PyroGenesis Canada's score of 0.22 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
PyroGenesis Canada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Unicycive Therapeutics beats PyroGenesis Canada on 10 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to Neumora Therapeutics?

PyroGenesis Canada (NASDAQ:PYRGF) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

PyroGenesis Canada has higher revenue and earnings than Neumora Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.53	-$21.12M	-$0.04	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

PyroGenesis Canada has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.95, meaning that its share price is 195% more volatile than the broader market.

Neumora Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 1,214.55%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, PyroGenesis Canada had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for PyroGenesis Canada and 0 mentions for Neumora Therapeutics. PyroGenesis Canada's average media sentiment score of 0.22 beat Neumora Therapeutics' score of 0.00 indicating that PyroGenesis Canada is being referred to more favorably in the media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Neumora Therapeutics	Neutral

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

PyroGenesis Canada and Neumora Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

PyroGenesis Canada (NASDAQ:PYRGF) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PyroGenesis Canada has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

PyroGenesis Canada has a net margin of -115.14% compared to NRx Pharmaceuticals' net margin of -691.81%.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

In the previous week, NRx Pharmaceuticals had 5 more articles in the media than PyroGenesis Canada. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 3 mentions for PyroGenesis Canada. NRx Pharmaceuticals' average media sentiment score of 0.29 beat PyroGenesis Canada's score of 0.22 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PyroGenesis Canada has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.53	-$21.12M	-$0.04	N/A
NRx Pharmaceuticals	$1.23M	102.09	-$28.62M	-$0.55	N/A

NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 1,089.66%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

NRx Pharmaceuticals beats PyroGenesis Canada on 8 of the 15 factors compared between the two stocks.

How does PyroGenesis Canada compare to MediciNova?

PyroGenesis Canada (NASDAQ:PYRGF) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

PyroGenesis Canada has a net margin of -115.14% compared to MediciNova's net margin of -1,168.70%. PyroGenesis Canada's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
MediciNova	-1,168.70%	-26.51%	-24.39%

In the previous week, MediciNova had 6 more articles in the media than PyroGenesis Canada. MarketBeat recorded 9 mentions for MediciNova and 3 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.22 beat MediciNova's score of 0.19 indicating that PyroGenesis Canada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PyroGenesis Canada has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

MediciNova has a consensus price target of $7.75, indicating a potential upside of 335.39%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MediciNova has lower revenue, but higher earnings than PyroGenesis Canada. MediciNova is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.53	-$21.12M	-$0.04	N/A
MediciNova	$410K	213.69	-$12M	-$0.21	N/A

Summary

MediciNova beats PyroGenesis Canada on 10 of the 17 factors compared between the two stocks.

How does PyroGenesis Canada compare to Immunic?

PyroGenesis Canada (NASDAQ:PYRGF) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immunic has a consensus target price of $35.43, indicating a potential upside of 345.08%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Immunic has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Immunic	N/A	-157.89%	-107.88%

In the previous week, PyroGenesis Canada had 3 more articles in the media than Immunic. MarketBeat recorded 3 mentions for PyroGenesis Canada and 0 mentions for Immunic. Immunic's average media sentiment score of 1.17 beat PyroGenesis Canada's score of 0.22 indicating that Immunic is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Immunic	Positive

PyroGenesis Canada has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Immunic has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Immunic. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.53	-$21.12M	-$0.04	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Summary

Immunic beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.75M	$12.20B	$7.13B	$13.32B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	-3.00	802.22	274.76	26.04
Price / Sales	4.46	755.91	614.48	93.14
Price / Cash	N/A	15.08	27.22	34.69
Price / Book	-18.00	10.47	11.13	6.35
Net Income	-$21.12M	$2.84B	$3.50B	$381.35M
7 Day Performance	14.21%	-1.67%	-1.88%	-0.70%
1 Month Performance	20.00%	-5.70%	-6.20%	-4.58%
1 Year Performance	7.33%	-2.27%	7.99%	1.51%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.18 -1.6%	N/A	+9.1%	$40.75M	$9.14M	N/A	90
UNCY Unicycive Therapeutics	2.9266 of 5 stars	$4.70 -2.3%	$18.75 +298.9%	-8.7%	$133.98M	$680K	N/A	22	Gap Up
NMRA Neumora Therapeutics	3.4232 of 5 stars	$0.68 -3.6%	$6.57 +869.8%	-72.7%	$132.11M	N/A	N/A	63
NRXP NRx Pharmaceuticals	1.8981 of 5 stars	$2.99 -1.3%	$34.50 +1,053.8%	-11.3%	$131.19M	$1.23M	N/A	29
MNOV MediciNova	2.718 of 5 stars	$2.58 -2.6%	$7.75 +200.4%	+39.1%	$130.44M	$410K	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. UNCY, NMRA, NRXP, MNOV, and IMUX

How does PyroGenesis Canada compare to Unicycive Therapeutics?

Summary

How does PyroGenesis Canada compare to Neumora Therapeutics?

Summary

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

Summary

How does PyroGenesis Canada compare to MediciNova?

Summary

How does PyroGenesis Canada compare to Immunic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. UNCY, NMRA, NRXP, MNOV, and IMUX

How does PyroGenesis Canada compare to Unicycive Therapeutics?

Do analysts recommend UNCY or PYRGF?

Which has more volatility & risk, UNCY or PYRGF?

Which has preferable earnings and valuation, UNCY or PYRGF?

Is UNCY or PYRGF more profitable?

Do institutionals and insiders have more ownership in UNCY or PYRGF?

Does the media favor UNCY or PYRGF?

Summary

How does PyroGenesis Canada compare to Neumora Therapeutics?

Which has better valuation & earnings, PYRGF or NMRA?

Which has more risk & volatility, PYRGF or NMRA?

Is PYRGF or NMRA more profitable?

Do analysts rate PYRGF or NMRA?

Does the media refer more to PYRGF or NMRA?

Do institutionals & insiders hold more shares of PYRGF or NMRA?

Summary

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

Do insiders & institutionals hold more shares of PYRGF or NRXP?

Which has more volatility & risk, PYRGF or NRXP?

Is PYRGF or NRXP more profitable?

Does the media refer more to PYRGF or NRXP?

Which has higher valuation and earnings, PYRGF or NRXP?

Do analysts rate PYRGF or NRXP?

Summary

How does PyroGenesis Canada compare to MediciNova?

Is PYRGF or MNOV more profitable?

Does the media refer more to PYRGF or MNOV?

Which has more volatility and risk, PYRGF or MNOV?

Do analysts rate PYRGF or MNOV?

Do institutionals & insiders believe in PYRGF or MNOV?

Which has stronger earnings and valuation, PYRGF or MNOV?

Summary

How does PyroGenesis Canada compare to Immunic?

Do insiders & institutionals believe in PYRGF or IMUX?

Do analysts prefer PYRGF or IMUX?

Is PYRGF or IMUX more profitable?

Does the media refer more to PYRGF or IMUX?

Which has more volatility and risk, PYRGF or IMUX?

Which has stronger valuation & earnings, PYRGF or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools